Next Article in Journal
Clinical Lymph Node Involvement as a Predictor for Cancer-Specific Survival in Patients with Penile Squamous Cell Cancer
Previous Article in Journal
Integrative Multi-Omics Analysis for the Determination of Non-Muscle Invasive vs. Muscle Invasive Bladder Cancer: A Pilot Study
Previous Article in Special Issue
Outcomes of Geriatric Patients with Hepatocellular Carcinoma
 
 
Communication

Liver Cancer-Specific Isoform of Serine Protease Inhibitor Kazal for the Detection of Hepatocellular Carcinoma: Results from a Pilot Study in Patients with Dysmetabolic Liver Disease

1
Department of Medical Sciences, University of Turin, 10126 Torino, Italy
2
Gastroenterology Unit, A.O.U. Città della Salute e della Scienza, 10126 Torino, Italy
3
Department of Sciences of Public Health and Pediatrics, University of Turin, 10126 Torino, Italy
4
Fujirebio Diagnostic AB, 41458 Gothenburg, Sweden
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
These authors contributed equally to this work.
Curr. Oncol. 2022, 29(8), 5457-5465; https://doi.org/10.3390/curroncol29080431
Received: 31 May 2022 / Revised: 10 July 2022 / Accepted: 29 July 2022 / Published: 31 July 2022
Reliable non-invasive biomarkers for the surveillance of patients at risk of hepatocellular carcinoma (HCC) development represent an unmet medical need. Recently, the liver-cancer-specific isoform of serine protease inhibitor Kazal (LC-SPIK) has been proposed as a valuable biomarker for the detection of HCC in patients with chronic liver disease of viral etiology. In the present study, we assessed the diagnostic accuracy of LC-SPIK, alone or in combination with standard serologic biomarkers (i.e., alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II, PIVKA-II), for the detection of HCC among patients with dysmetabolic liver disease. A total of 120 patients with non-alcoholic fatty liver disease (NAFLD), including 62 patients with a diagnosis of HCC and 58 with cirrhosis but without tumor, were retrospectively analyzed. The serum levels of LC-SPIK were measured by enzyme-linked immunosorbent assay (ImCare Biotech, Doylestown, PA). The serum LC-SPIK values were significantly different between patients with HCC (24.3, 17.6–39.8 ng/mL) and those with cirrhosis but without tumor (11.7, 8.7–18.2 ng/mL) (p < 0.001). By receiver operating characteristic curve analysis, we observed an area under the curve (AUC) of 0.841 for the detection of HCC; the combination with PIVKA-II further increased the accuracy to AUC = 0.926 (cross-validation). The promising results observed in the present pilot study foster additional research to investigate the usefulness of LC-SPIK for the stratification of the risk of HCC development in patients with NAFLD and advanced liver disease. View Full-Text
Keywords: diagnostic accuracy; HCC; LC-SPIK; NAFLD; PIVKA-II diagnostic accuracy; HCC; LC-SPIK; NAFLD; PIVKA-II
Show Figures

Figure 1

MDPI and ACS Style

Caviglia, G.P.; Nicolosi, A.; Abate, M.L.; Carucci, P.; Rosso, C.; Rolle, E.; Armandi, A.; Aneli, S.; Olivero, A.; Risso, A.; Ribaldone, D.G.; Fermer, C.; Saracco, G.M.; Gaia, S.; Bugianesi, E. Liver Cancer-Specific Isoform of Serine Protease Inhibitor Kazal for the Detection of Hepatocellular Carcinoma: Results from a Pilot Study in Patients with Dysmetabolic Liver Disease. Curr. Oncol. 2022, 29, 5457-5465. https://doi.org/10.3390/curroncol29080431

AMA Style

Caviglia GP, Nicolosi A, Abate ML, Carucci P, Rosso C, Rolle E, Armandi A, Aneli S, Olivero A, Risso A, Ribaldone DG, Fermer C, Saracco GM, Gaia S, Bugianesi E. Liver Cancer-Specific Isoform of Serine Protease Inhibitor Kazal for the Detection of Hepatocellular Carcinoma: Results from a Pilot Study in Patients with Dysmetabolic Liver Disease. Current Oncology. 2022; 29(8):5457-5465. https://doi.org/10.3390/curroncol29080431

Chicago/Turabian Style

Caviglia, Gian Paolo, Aurora Nicolosi, Maria Lorena Abate, Patrizia Carucci, Chiara Rosso, Emanuela Rolle, Angelo Armandi, Serena Aneli, Antonella Olivero, Alessandra Risso, Davide Giuseppe Ribaldone, Christian Fermer, Giorgio Maria Saracco, Silvia Gaia, and Elisabetta Bugianesi. 2022. "Liver Cancer-Specific Isoform of Serine Protease Inhibitor Kazal for the Detection of Hepatocellular Carcinoma: Results from a Pilot Study in Patients with Dysmetabolic Liver Disease" Current Oncology 29, no. 8: 5457-5465. https://doi.org/10.3390/curroncol29080431

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop